Form 4: C4 Therapeutics Director Laura Bessen Granted Stock Options

C4 Therapeutics, Inc. Director Laura Bessen was granted 35,500 stock options with an exercise price of $1.44, vesting upon the earlier of June 18, 2026, or the next annual stockholders' meeting.

Summary

• Laura Bessen, a Director of C4 Therapeutics, Inc. (CCCC), was granted 35,500 stock options.
• The transaction date for this grant was June 18, 2025.
• Each stock option has an exercise price of $1.44.
• The options are for Common Stock, with 35,500 shares underlying the grant.
• The options will vest and become exercisable in full upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders.
• Vesting is subject to Ms. Bessen's continued service as a member of the Board on the vesting date.
• The expiration date for these stock options is June 17, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. There are no negative implications from this routine filing.

Positives

• The grant of stock options aligns the interests of Director Laura Bessen with those of the shareholders, as her compensation is tied to the company's future stock performance.
• This is a standard form of compensation for directors, indicating continuity in corporate governance practices.

Future Outlook

The stock options granted to Director Laura Bessen are set to vest upon the earlier of June 18, 2026, or the next annual meeting of stockholders, contingent on her continued service on the Board. This indicates a future milestone for the options to become exercisable.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize long-term commitment and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector.
• Without specific details on C4 Therapeutics' peer group compensation policies or the director's overall compensation package, a direct quantitative comparison to industry benchmarks for this specific grant size is not possible from this document alone. However, the mechanism of equity-based compensation is consistent with industry norms.

Corporate Governance

Related Party Transactions

• The grant of stock options to Laura Bessen, a Director, constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.
• Director (Laura Bessen): Receives equity-based compensation, incentivizing long-term commitment and performance.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stock Option Grant, Insider Transaction, Director Compensation, SEC Form 4, Beneficial Ownership